Aileron Therapeutics News Releases http://investors.aileronrx.com/ Aileron Therapeutics News Releases en Aileron Therapeutics Reports First Quarter 2019 Financial Results http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-reports-first-quarter-2019-financial Aileron announced a $26 million capital raise via PIPE transaction  Enrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified tumors underway and ahead of schedule   ALRN-6924/palbociclib Phase 2a interim data in MDM2-amplified Wed, 08 May 2019 16:57:00 -0400 Aileron Therapeutics News Releases 7456 Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8 http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-report-first-quarter-2019-financial-results WATERTOWN, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that the Company will report financial results for its first quarter ended March Wed, 01 May 2019 18:31:00 -0400 Aileron Therapeutics News Releases 7446 Aileron Therapeutics Completes $26M Private Placement http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-completes-26m-private-placement Satter Medical Technology Partners led the private placement; Dr. Nolan Sigal , Partner at Satter Management, joins Aileron’s Board of Directors WATERTOWN, Mass. , April 03, 2019 (GLOBE NEWSWIRE) --   Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized Wed, 03 Apr 2019 12:15:00 -0400 Aileron Therapeutics News Releases 7341 Aileron Therapeutics Announces Pricing of $26M Private Placement http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-announces-pricing-26m-private-placement WATERTOWN, Mass. , March 29, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, announced today that it has entered into a securities purchase agreement with a group of Fri, 29 Mar 2019 09:00:00 -0400 Aileron Therapeutics News Releases 7311 Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-appoints-kathryn-gregory-chief-business WATERTOWN, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseases, today announced that Kathryn Gregory has been named Chief Business Officer (CBO). Mon, 04 Mar 2019 09:00:00 -0500 Aileron Therapeutics News Releases 7286 Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-commences-enrollment-phase-2a-expansion WATERTOWN, Mass. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that the first patient has been enrolled in a Phase 2a expansion cohort Wed, 16 Jan 2019 12:47:00 -0500 Aileron Therapeutics News Releases 7266 Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting http://investors.aileronrx.com/news-releases/news-release-details/aileron-presents-interim-alrn-6924-data-ptcl-mds-and-aml Results in relapsed/refractory peripheral T-cell lymphoma (PTCL) demonstrate single-agent clinical proof-of-concept Combination therapy dose-escalation with low-dose cytarabine (Ara-C) in myelodysplastic syndrome (MDS) patients who failed hypomethylating agents shows promising activity; expansion Tue, 04 Dec 2018 09:13:00 -0500 Aileron Therapeutics News Releases 7251 Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers http://investors.aileronrx.com/news-releases/news-release-details/aileron-enters-clinical-trial-collaboration-pfizer-evaluate-alrn WATERTOWN, Mass. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to Tue, 27 Nov 2018 08:00:00 -0500 Aileron Therapeutics News Releases 7226 Aileron Therapeutics Reports Third Quarter 2018 Financial Results http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-reports-third-quarter-2018-financial Manuel Aivado, MD, PhD, promoted to President and Chief Executive Officer Vojislav Vukovic , MD, appointed Senior Vice President, Chief Medical Officer, and Allen Annis , PhD, promoted to Senior Vice President, Research Interim ALRN-6924 clinical data for PTCL, AML, and MDS patients to be presented Wed, 07 Nov 2018 16:10:00 -0500 Aileron Therapeutics News Releases 7211 Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer http://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-appoints-vojislav-vukovic-md-phd-chief Allen Annis , PhD, promoted to Senior Vice President of Research WATERTOWN, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that Vojislav Mon, 05 Nov 2018 16:05:00 -0500 Aileron Therapeutics News Releases 7186